JP6152107B2 - クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 - Google Patents

クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 Download PDF

Info

Publication number
JP6152107B2
JP6152107B2 JP2014530307A JP2014530307A JP6152107B2 JP 6152107 B2 JP6152107 B2 JP 6152107B2 JP 2014530307 A JP2014530307 A JP 2014530307A JP 2014530307 A JP2014530307 A JP 2014530307A JP 6152107 B2 JP6152107 B2 JP 6152107B2
Authority
JP
Japan
Prior art keywords
cdr
seq
antibody
sequence shown
tcda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014530307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501286A (ja
Inventor
ポール ハンフリーズ、デイヴィッド
ポール ハンフリーズ、デイヴィッド
ジョン ライトウッド、ダニエル
ジョン ライトウッド、ダニエル
ルイーズ タイソン、ケリー
ルイーズ タイソン、ケリー
エドワード オーモンド ナイト、デイヴィッド
エドワード オーモンド ナイト、デイヴィッド
ジャンニーヌ マデレーヌ エルヴェ、カリーヌ
ジャンニーヌ マデレーヌ エルヴェ、カリーヌ
エリザベス コンプソン、ジョアン
エリザベス コンプソン、ジョアン
ジョン ティモシー ペイジ、マシュー
ジョン ティモシー ペイジ、マシュー
チャールズ ペイン、アンドリュー
チャールズ ペイン、アンドリュー
ルイーズ フィッシャー、ニコラ
ルイーズ フィッシャー、ニコラ
マッケンジー、ブレンドン
コックス、マシュー
Original Assignee
ユセベ ファルマ ソシエテ アノニム
ユセベ ファルマ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6152107(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユセベ ファルマ ソシエテ アノニム, ユセベ ファルマ ソシエテ アノニム filed Critical ユセベ ファルマ ソシエテ アノニム
Publication of JP2015501286A publication Critical patent/JP2015501286A/ja
Application granted granted Critical
Publication of JP6152107B2 publication Critical patent/JP6152107B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014530307A 2011-09-16 2012-09-10 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 Expired - Fee Related JP6152107B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US61/535,532 2011-09-16
US201261638731P 2012-04-26 2012-04-26
US61/638,731 2012-04-26
PCT/GB2012/052222 WO2013038156A1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104698A Division JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Publications (2)

Publication Number Publication Date
JP2015501286A JP2015501286A (ja) 2015-01-15
JP6152107B2 true JP6152107B2 (ja) 2017-06-21

Family

ID=46881094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014530307A Expired - Fee Related JP6152107B2 (ja) 2011-09-16 2012-09-10 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2017104698A Expired - Fee Related JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2019187271A Ceased JP2020037555A (ja) 2011-09-16 2019-10-11 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017104698A Expired - Fee Related JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2019187271A Ceased JP2020037555A (ja) 2011-09-16 2019-10-11 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Country Status (30)

Country Link
US (2) US10752676B2 (enExample)
EP (2) EP3617227A3 (enExample)
JP (3) JP6152107B2 (enExample)
KR (1) KR20140063825A (enExample)
CN (2) CN108424449A (enExample)
AU (1) AU2012307157B2 (enExample)
BR (1) BR112014006175B1 (enExample)
CA (1) CA2848611A1 (enExample)
CL (1) CL2014000491A1 (enExample)
CO (1) CO6930310A2 (enExample)
CY (1) CY1121673T1 (enExample)
DK (1) DK2758432T3 (enExample)
EA (1) EA032475B1 (enExample)
EC (1) ECSP14013316A (enExample)
ES (1) ES2729278T3 (enExample)
HK (1) HK1199463A1 (enExample)
HR (1) HRP20190917T1 (enExample)
HU (1) HUE043661T2 (enExample)
IL (1) IL231167A0 (enExample)
LT (1) LT2758432T (enExample)
MX (1) MX2014002769A (enExample)
PE (1) PE20141547A1 (enExample)
PH (1) PH12014500456A1 (enExample)
PL (1) PL2758432T3 (enExample)
PT (1) PT2758432T (enExample)
SG (2) SG10201701055WA (enExample)
SI (1) SI2758432T1 (enExample)
TN (1) TN2014000101A1 (enExample)
WO (1) WO2013038156A1 (enExample)
ZA (1) ZA201402760B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020037555A (ja) * 2011-09-16 2020-03-12 ユセベ ファルマ ソシエテ アノニム クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501877A (ja) * 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CA2939969A1 (en) * 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
EP3283103A4 (en) * 2015-04-15 2018-12-05 Medimmune, LLC Methods for treating clostridium difficile infection and associated disease
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
BR112019012203A2 (pt) * 2016-12-14 2019-11-12 Beijing Genomics Inst At Shenzhen marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用
CN121379975B (zh) * 2025-12-25 2026-04-17 天津一瑞生物科技股份有限公司 抗TcdB毒素杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
ATE544354T1 (de) * 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2366626T3 (es) * 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
EP1830635B1 (en) 2004-12-27 2015-10-28 Huntsman Corporation Australia Pty Limited Reduced foam dispersions and formulations therefor
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535350B1 (en) * 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
EP2271366A4 (en) * 2008-02-28 2012-06-20 3M Innovative Properties Co ANTIBODIES DIFFICULT CLOSTRIDIUM SPORES AND USES THEREOF
KR20180005753A (ko) * 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
US8709428B2 (en) * 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
AU2011239470B2 (en) * 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
BR112014006175B1 (pt) * 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2014061783A1 (ja) * 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020037555A (ja) * 2011-09-16 2020-03-12 ユセベ ファルマ ソシエテ アノニム クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Also Published As

Publication number Publication date
HRP20190917T1 (hr) 2019-07-26
EP2758432B1 (en) 2019-03-06
NZ623293A (en) 2016-05-27
TN2014000101A1 (en) 2015-07-01
CA2848611A1 (en) 2013-03-21
MX2014002769A (es) 2014-06-11
PT2758432T (pt) 2019-06-14
JP2017149773A (ja) 2017-08-31
CN108424449A (zh) 2018-08-21
BR112014006175A2 (pt) 2017-04-04
EA032475B1 (ru) 2019-06-28
ES2729278T3 (es) 2019-10-31
IL231167A0 (en) 2014-04-30
CY1121673T1 (el) 2020-07-31
ECSP14013316A (es) 2014-08-29
PH12014500456A1 (en) 2014-04-14
CN103958544A (zh) 2014-07-30
HUE043661T2 (hu) 2019-08-28
BR112014006175B1 (pt) 2020-02-11
SG11201400193SA (en) 2014-05-29
ZA201402760B (en) 2016-03-30
EA201400345A1 (ru) 2014-09-30
KR20140063825A (ko) 2014-05-27
SG10201701055WA (en) 2017-03-30
PE20141547A1 (es) 2014-10-25
DK2758432T3 (da) 2019-06-03
CN103958544B (zh) 2018-04-24
WO2013038156A1 (en) 2013-03-21
US10752676B2 (en) 2020-08-25
SI2758432T1 (sl) 2019-07-31
JP2015501286A (ja) 2015-01-15
JP6603685B2 (ja) 2019-11-06
EP3617227A2 (en) 2020-03-04
CO6930310A2 (es) 2014-04-28
US20200377578A1 (en) 2020-12-03
AU2012307157B2 (en) 2017-08-03
LT2758432T (lt) 2019-06-10
EP3617227A3 (en) 2020-06-03
HK1199463A1 (en) 2015-07-03
EP2758432A1 (en) 2014-07-30
US20140348844A1 (en) 2014-11-27
PL2758432T3 (pl) 2019-08-30
CL2014000491A1 (es) 2014-12-26
AU2012307157A1 (en) 2014-04-24
JP2020037555A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
JP6603685B2 (ja) クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP7724712B2 (ja) ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用
JP6159854B2 (ja) クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
ES2795667T3 (es) Composiciones para inhibir la activación del complemento dependiente de MASP-2
ES2689470T3 (es) Anticuerpos de Fab-Fv de conector único y métodos para producirlos
TW202005981A (zh) 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
JP2014237714A (ja) 抗ａ型インフルエンザウイルス中和抗体およびその使用
TW202019957A (zh) TGFβ1抑制劑及其用途
JP2013543382A (ja) 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
US20220169714A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
CA3127943A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
WO2010079161A1 (en) A b cell depleting agent for the treatment of atherosclerosis
NZ623293B2 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP4735645A2 (en) Methods for detection and treatment of cancer
WO2026062579A1 (en) Compositions and methods for protein delivery to cells
WO2025213047A1 (en) Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170526

R150 Certificate of patent or registration of utility model

Ref document number: 6152107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees